Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its target price increased by Wedbush from $103.00 to $105.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

DNTH has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a research note on Monday, March 9th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Raymond James Financial upgraded Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $63.00 to $123.00 in a research note on Tuesday, March 10th. Finally, Stifel Nicolaus set a $120.00 price target on Dianthus Therapeutics in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Up 0.2%

Shares of DNTH opened at $90.42 on Wednesday. Dianthus Therapeutics has a 12-month low of $16.64 and a 12-month high of $96.50. The firm has a market capitalization of $4.92 billion, a price-to-earnings ratio of -21.89 and a beta of 1.18. The stock’s 50-day moving average price is $80.35 and its 200 day moving average price is $55.95.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.25. Dianthus Therapeutics had a negative return on equity of 38.79% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Equities research analysts expect that Dianthus Therapeutics will post -4.46 EPS for the current year.

Insider Buying and Selling

In other Dianthus Therapeutics news, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,021 shares of company stock valued at $26,564,008 over the last ninety days. Company insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC acquired a new stake in Dianthus Therapeutics during the first quarter valued at approximately $40,713,000. Bank of New York Mellon Corp boosted its holdings in Dianthus Therapeutics by 150.8% during the first quarter. Bank of New York Mellon Corp now owns 188,412 shares of the company’s stock valued at $15,812,000 after purchasing an additional 113,280 shares in the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in shares of Dianthus Therapeutics in the first quarter valued at approximately $386,000. First Horizon Corp bought a new position in shares of Dianthus Therapeutics in the first quarter valued at approximately $32,000. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Dianthus Therapeutics in the first quarter valued at approximately $409,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.